AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

The ruling by U.S. District Judge Harvey Bartle in Philadelphia came in an antitrust lawsuit filed in 2014 by the Federal Trade Commission against AbbVie and its partner Besins Healthcare Inc.

The decision followed a non-jury trial that tested the ability of the U.S. regulator to fight efforts by major pharmaceutical companies to prevent the sale of cheaper generic versions of their drugs.

TRENDING NOW

iQOO 12 with SD 8 Gen 3 launch set to launch in India soon

NPS (National Pension System): How to create a corpus of Rs 5 crore with Rs 442 investment/day? After retirement, you will get Rs 2.5 lakh every month

Mcap of seven of top-10 most valued firms added Rs 3.04 lakh crore; HDFC Bank, LIC biggest gainers

FPIs invest Rs 26,505 crore in equities in 1st six sessions of December

India vs South Africa 1st T20I Free Live Streaming: When and Where to watch IND VS SA T20I series Match LIVE on Mobile Apps, TV, Laptop, Online

Manu Ahuja, CEO of Jubilant Agri and Consumer Products, passes away

Post Office Time Deposit Scheme: Interest up to 7.5%, guaranteed returns, fixed income, preclosure rules, other benefits

CLAT 2023 result to be released today on consortiumofnlus.ac.in - Final answer key out

Tata Motors to hike commercial vehicle prices by up to 3% from January 1

NT Awards 2023: Zee Business shines in five categories

Centre makes air-conditioned truck cabin mandatory from October 2025

Animal Box Office Collection: Ranbir Kapoor-starrer touches Rs 600 crore mark worldwide | Check OTT release details

India seeks to settle WTO import duty dispute with EU on ICT goods through free trade talks

COVID-19 Update: India records 148 new coronavirus cases, infection tally stands at 4.50 crore

Sebi plans to introduce 'fast track' concept for public issuance of debt securities

The FTC had accused Chicago-based AbbVie and Besins of filing baseless patent infringement lawsuits against competitors to delay the launch of their generic products.

The FTC, which had sought $1.35 billion, said the order was the largest monetary award ever in an antitrust case that it litigated in court. Bartle said liability would be apportioned between AbbVie and Besins according their agreed royalty rates.

"It sends a clear signal that pharmaceutical companies can’t use baseless litigation to forestall competition from low-cost generics," FTC Chairman Joe Simons said in a statement.

Representatives for AbbVie did not respond to requests for comment. A lawyer for Besins had no immediate comment.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)